News
-
-
-
PRESS RELEASE
Psycheceutical Bioscience Strategically Pivots Into the Brain-Computer Interface (BCI) Space
Psycheceutical Bioscience, Inc. appoints Neilank K. Jha, MD, as Executive Chairman and CEO to lead a turnaround, shifting focus from the psychedelic space to Brain-Computer Interface (BCI) technology. The company's mission is to develop products to improve the quality of life and survival rate of patients with neurological conditions. With partnerships with top-tier academic institutions and a prototype smart medical device in development, the company aims to revolutionize neurological therapies. The Board is exploring options to cure regulatory filing deficiencies and enable future corporate actions. NeuraSeed BCI, the next-generation neuroscience company, is focused on deep-brain implantation technology and brain-computer interfaces, aiming to transform neurological therapies for global benefit. -
-
-
-
-
-
Revolutionizing Fire Camps: NUE's Sustainable Power Solutions Shine at USDA Technology & Development Center
-
Save A Train Continues to Innovate with Rail Enrichment
-
Cameron Ashley Building Products Opens Third Location in the Badger State
-
Event Tickets Center is Named Official Secondary Ticketing Reseller Partner for Most Valuable Promotions and the Historic Jake Paul vs. Mike Tyson Fight
-
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect
-
Amendment of the terms and conditions of the bond completed; Bondholders can convert bonds into shares
-
secunet Security Networks AG successfully holds Annual General Meeting – Broad approval for all proposed resolutions
-
TUI AG: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
-
Fuller, Smith & Turner PLC: Transaction in own shares
-
AngloGold Ashanti US$9.0m (A$13.5m) Gold Farm-in Agreement
-
2024 Annual General Meeting: approval of all resolutions submitted to the Meeting
-
PR – ICADE – Success of the cash tender offer for a total amount of €350 million
-
AMOEBA: ORDINARY AND EXTRAORDINARY GENERAL MEETING OF 27 JUNE 2024 - Availability of preliminary documents
-
Availability of preparatory documents for the annual general meeting of June 13, 2024
-
Safran’s 2024 Annual General Meeting